Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 469

Results For "C"

10349 News Found

Brenntag Specialties and Zeochem expand collaboration for Pharma EMEA
Supply Chain | November 17, 2023

Brenntag Specialties and Zeochem expand collaboration for Pharma EMEA

Collaboration enables Brenntag to serve pharma customers in EMEA with chromatography silica gels


Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting
Drug Approval | November 17, 2023

Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer


Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer
Drug Approval | November 16, 2023

Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer

Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient


Sanofi completes closing for potential first-in-class vaccine against ExPEC
News | November 16, 2023

Sanofi completes closing for potential first-in-class vaccine against ExPEC

Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis


JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr
News | November 15, 2023

JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr

Reports revenue growth of 9% to INR 882 crores in Q2 FY24


IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr
News | November 15, 2023

IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr

EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ


Kesin Pharma announces FDA approval and availability of Likmez oral suspension
Drug Approval | November 15, 2023

Kesin Pharma announces FDA approval and availability of Likmez oral suspension

Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing


Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Clinical Trials | November 15, 2023

Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program

Phase 3 data expected in the second half of 2024


Wockhardt Q2 FY24 consolidated loss lowers at Rs. 77 Cr
News | November 15, 2023

Wockhardt Q2 FY24 consolidated loss lowers at Rs. 77 Cr

Wockhardt has reported total income of Rs. 777 crores during the period ended September 30, 2023


Natco Pharma posts consolidated Q2F Y24 PAT of Rs. 369 Cr
News | November 15, 2023

Natco Pharma posts consolidated Q2F Y24 PAT of Rs. 369 Cr

Natco Pharma has reported total income of Rs. 1060.8 crores during the period ended September 30, 2023